NEW YORK (GenomeWeb News) — BioSeek said today that it has renewed and expanded an agreement to profile and guide optimization of lead compounds for the drug company UCB.
South San Francisco, Calif.-based BioSeek said it will profile selected chemical and biological entities and guide lead optimization of a specific phenotypic hit identified by UCB and characterized using the company’s BioMap screens.
Under the one-year agreement, which expands a 2007 pact, BioSeek will receive an up-front licensing fee, funding for research, and both clinical and preclinical milestone payments based on candidate advancement using the BioMap platform.
The BioMap System uses predictive human cell-based models to generate activity profiles of potential drug candidates.
“Our 2007 collaboration identified specific areas of high interest to UCB where the BioMap platform could be productively applied to UCB projects, and those form the basis of the new agreement encompassing two major programs in bioactive annotation and lead optimization,” BioSeek CEO Michael Venuti said in a statement. “By focusing on pharmacological outcome in a defined set of validated human cell-based screens, novel bioactivity can be detected, and anecdotally observed activity can be optimized.”
UCB’s primary focus is on developing drugs to treat central nervous system disorders, inflammation, and cancer.